

Reducing seed waste and increasing value of dynamic intraoperative implantation of Pd-103 seeds in prostate brachytherapy

Peter K. Taylor¹ | Adam C. Riegel^{1,2}

¹Northwell Health System, Department of Radiation Medicine, Center for Advanced Medicine, Lake Success, NY, USA

²Hofstra Northwell School of Medicine, Hempstead, NY, USA

Author to whom correspondence should be addressed. Peter K. Taylor.

Email: ptaylor3@northwell.edu.

Abstract

Several nomograms exist for ordering palladium-103 seeds for permanent prostate seed implants (PSI). Excess seeds from PSIs pose additional radiation safety risks and increase the cost of care. This study compared five nomograms to clinical data from dynamic modified-peripheral intraoperative PSI to determine (a) the cause of excess seeds and (b) the optimal nomogram for our institution. Pre- and intraoperative patient data were collected for monotherapy PSIs and compiled into a clinical database. All patients were prescribed 125 Gy with dose coverage of D90% = 100% to the planning target volume (PTV) using ¹⁰³Pd seeds with mean air-kerma strength ($\overline{S_K}$) of 2 U. Seeds were ordered based upon an in-house nomogram as a function of preoperative prostate volume and prescription dose. Preoperative prostate volume was assessed with transrectal ultrasound. If any of the following four conditions were not met: (a) preoperative volume = intraoperative volume, (b) D90% = 100%, (c) $\overline{S_K} = 2U$, and (d) seed ordering matched the in-house nomogram, then a normalization factor was applied to the number of seeds used intraoperatively to meet all four conditions. Four published nomograms, an in-house nomogram, and the normalized number of implanted seeds for each patient were plotted against intraoperative prostate volume. Of the 226 patients, 223 had excess seeds at the completion of their PSI. On average, $25.7 \pm 9.9\%$ of ordered seeds were not implanted. Excess seeds were separated into two categories, accounted-for excess, determined by the four normalization factors, and residual excess, assumed to be due to overordering. The upper 99.9% CI linear fit of the normalized clinical data plus a 5% “cushion” may provide a more reasonable nomogram for ¹⁰³Pd seed ordering for our institution. Nomograms customized for individual institutions may reduce seed waste, thereby reducing radiation safety risks and increasing the value of prostate brachytherapy.

PACS

87.53.Jw

KEY WORDS

brachytherapy, nomogram, palladium-103, prostate seed implant

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2018 The Authors. *Journal of Applied Clinical Medical Physics* published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.

1 | INTRODUCTION

Many treatment options, such as radical prostatectomy, external beam radiation therapy (EBRT), brachytherapy, hormonal treatment, and active surveillance, exist for patients with prostate cancer.¹ Transperineal interstitial permanent prostate brachytherapy (TIPPB) for early stage prostate cancer is an outpatient procedure involving insertion of radioactive seeds into the prostate under transrectal ultrasound guidance.¹ Current radioisotopes used in TIPPB include ¹²⁵I, ¹⁰³Pd, and ¹³¹Cs.¹⁻⁴ At our institution, ¹⁰³Pd seeds are implanted using a dynamic intraoperative technique¹⁻³ and the workflow for seed ordering, implantation, and postimplant dosimetry is similar to that described in AAPM TG-64.² The workflow is as follows: (a) ¹⁰³Pd seeds are ordered using a nomogram based on preoperative prostate volume, (b) the ¹⁰³Pd seeds are independently assayed, (c) the ¹⁰³Pd seeds are implanted into the prostate under transrectal ultrasound guidance, (d) postoperative excess ¹⁰³Pd seeds (if applicable) are counted and disposed of by the medical physicist, and (e) postoperative dosimetry is performed approximately 4 weeks later.

Preoperative imaging of the patient's prostate is used to determine the number of ¹⁰³Pd seeds to be ordered. At our institution, a nomogram comparing total recommended air-kerma strength (U) and prostate volume (cm³) is used to determine the recommended total air-kerma strength for the implant. The number of required seeds is found by dividing the total air-kerma strength by the requested air-kerma strength per seed. In our clinical experience, we have often found that there are a substantial number of excess ¹⁰³Pd seeds after prostate seed implants. Reducing the number of unused seeds can reduce radiation safety risks, reduce cost, and increase the value of prostate brachytherapy in the context of value-based medicine, defined as, "the practice of medicine incorporating the highest level of evidence-based data with the patient-perceived value conferred by healthcare interventions for the resources expended."⁵ The purpose of this study was, (a) determine the cause of excess ¹⁰³Pd seeds in dynamic intraoperative TIPPB and (b) determine the optimal nomogram for our institution.

2 | MATERIALS AND METHODS

Prostate cancer patients who received monotherapy using ¹⁰³Pd to a dose of 125 Gy were retrospectively included in the chart review. Relevant dosimetric and volumetric pre-, intra-, and postoperative measurements were compiled into a clinical database.

2.A | Excess seeds

The clinical database was used to determine the number of excess seeds for each patient. The number of excess seeds (N_{XS}) is defined in eq. (1).

$$N_{XS} = (\text{number of seeds ordered}) - (\text{number of seeds used intra-operatively}) \quad (1)$$

The total number of excess seeds can be separated into two categories, accounted-for excess (A_{XS}) and residual excess (R_{XS}). The

quantity A_{XS} is equal to the sum of the number of excess seeds remaining after an implant (n) which can be attributed to a specific reason (i) [eq. (2)]. The value of n_i can be positive or negative.

$$A_{XS} = \sum_i n_i \quad (2)$$

Excess seeds that could not be attributed to a specific cause were considered "residual." The quantity R_{XS} is equal to the number of excess seeds less the number of accounted-for excess seeds [eq. (3)].

$$R_{XS} = N_{XS} - A_{XS} \quad (3)$$

We identified four potential causes of excess seeds which are summarized in Table 1 and described in greater detail below. The value n_{vol} was calculated by taking the difference between the numbers of seeds which should have been ordered for each respective volume (preoperative and intraoperative) based upon the in-house nomogram. If preoperative prostate volume was greater than intraoperative prostate volume, additional, unnecessary seeds were ordered, i.e., $n_{vol} > 0$. If the intraoperative prostate volume was greater than the preoperative volume, more seeds were used than anticipated, which lowered the expected number of excess seeds at the end of the procedure, i.e., $n_{vol} < 0$.

The value n_{order} was the difference between what was ordered and what should have been ordered based on the in-house nomogram and the preoperative prostate volume. The output of the nomogram is total recommended air-kerma strength. When this value is converted into number of seeds using vendor specified air-kerma strength per seed, it is not necessarily an integer. For simplicity in ordering and to insure enough seeds were present for the procedure, nomogram results were frequently rounded up to the nearest multiple of five. If more seeds were ordered than indicated by the nomogram, the result is a known excess compared to the nomogram, i.e., $n_{order} > 0$. If fewer seeds were ordered than indicated by the nomogram, the result is a known seed deficit, i.e., $n_{order} < 0$.

TABLE 1 Variables which contribute to deviations between the expected number of seeds used intraoperatively and actual number of seeds used intraoperatively.

Reasons for excess seeds	Description	Number of excess seeds due to reason (i)
Change in prostate volume	Preoperative prostate volume \neq intraoperative prostate volume	n_{vol}
Intraoperative D90%	Intraoperative D90% \neq 100% (i.e., a "hot" or "cold" implant)	$n_{D90\%}$
Mean air-kerma strength	Mean air-kerma strength (S_k) \neq 2 U per seed	n_U
Ordering	Number of ordered seeds deviated from nomogram	n_{order}

All patients were prescribed 125 Gy with dose coverage of $D90\% = 100\%$ to the planning target volume (PTV). If the intraoperative $D90\%$ was less than 100%, i.e., a “cold implant,” then not enough seeds were used during the implant resulting in a known seed excess at the end of the procedure, i.e., $n_{D90\%}$. If the intraoperative $D90\%$ was greater than 100%, more seeds were used than anticipated which lowered the number of excess seeds at the end of the procedure, i.e., $n_{D90\%}$. If the mean air-kerma strength ($\overline{S_K}$) for a batch of seeds was greater than 2 U per seed, fewer seeds were required to meet the prescription dose of $D90\% = 100\%$ to the PTV resulting in a known seed excess, i.e., n_U . If the mean air-kerma strength ($\overline{S_K}$) for a batch of seeds was less than 2 U per seed, a greater number of seeds were required to meet the prescription dose of $D90\% = 100\%$ to the PTV resulting in a known seed deficit, i.e., n_U .

2.B | Clinical data normalization parameters

Once the cause of excess seeds was determined, the number of seeds used intraoperatively per patient was linearly normalized such that $\overline{S_K} = 2$ U and the intraoperative $D90\%$ was equal to 100%. The normalized number of ^{103}Pd seeds vs intraoperative prostate volume for each patient was plotted against intraoperative prostate volume and the upper 99.9% confidence interval of the patient data was generated.

3 | RESULTS

Between 2010 and 2015, our institution treated 251 patients with TIPPB using ^{103}Pd to a dose of 125 Gy. Pre-, intra-, and postoperative assessments were measured and compiled into a clinical database. For this study, exclusion criteria were: (a) an absolute difference greater than 20% between the intra- and postoperative $D90\%$ to the PTV ($n = 20$), (b) postoperative data were not available ($n = 2$), and (c) the combined modality therapy (external beam radiation therapy and TIPPB) nomogram was used to order seeds ($n = 3$). This left $n = 226$ patients in the study.

3.A | Excess seeds

Table 2 lists patient-specific assessments for three sample patients. Table 3 shows the calculation performed using the assessments in

Table 2 to determine n_i and subsequently N_{XS} , A_{XS} , and R_{XS} . A negative sign in Table 3 indicates that variable contributed positively toward R_{XS} , that is, there should have been more seeds at the end of the procedure due to that specific variable.

Of the 226 prostate seed implants, 98.6% ($n = 223$) had excess seeds. On average (± 1 standard deviation), there were 29.2 ± 13.2 excess seeds after the completion of a prostate seed implant. On average, $25.7 \pm 9.9\%$ of ordered seeds were not implanted. The percentage of ordered seeds which were wasted is the quotient of the number of excess seeds to the number of seeds ordered (eq. 4). Figure 1 shows the distribution of the percentage of ordered seeds which were wasted.

$$\text{Percentage of ordered seeds which were wasted} = \frac{\# \text{ of excess seeds}}{\# \text{ of seeds ordered}} \times 100\% \quad (4)$$

We found that none of the four parameters identified above contributed substantially to seed excess. In the cases where the intraoperative volume was greater than preoperative volume (53% of implants, $n = 117$), more seeds were used than anticipated to accommodate the larger prostate. In the cases where the implant had a $D90\% > 100\%$, i.e., a “hot implant” (72% of implants, $n = 159$), more seeds were used than anticipated which should have contributed towards the final number of excess seeds. In the cases where the mean air-kerma strength was greater than 2 U (43% of implants, $n = 98$), more seeds were used than anticipated which should have contributed towards the number of excess seeds. The value of n_i was on average negative for each “i.” The consequence of $\bar{n}_i < 0$ means the number of residual-excess seeds was on average greater than the physical number of excess seeds. On average, $30.7 \pm 7.1\%$ of ordered seeds were R_{XS} . Table 4 shows the average N_{XS} , R_{XS} , and n_i .

3.2. | Nomogram


The clinical data, after being normalized such that $\overline{S_K} = 2$ U and $D90\% = 100\%$, was compared to five nomograms: AAPM TG-64,² Anderson⁶ (Memorial-Sloan Kettering Cancer Center, 1993), Stock³ (Mt. Sinai, 1995), Wang⁷, and our in-house nomogram currently in use since 2010 (Fig. 2). There were differences between prescription doses which required linear scaling, for example, Anderson uses a prescription dose of 115 Gy for ^{103}Pd . If the AAPM TG-64 or

TABLE 2 Patient-specific assessments for three sample patients.

Patient-specific assessments								
Patient	I Preoperative volume (cm ³)	II # of seeds to order (Vol _{pre-op})	III # of seeds ordered	IV Intraoperative volume (cm ³)	V # of seeds to order (Vol _{i-o})	VI # of seeds used	VII Mean S_K (U)	VIII D90% _{i-o}
A	28.0	98	95	22.7	85	56	2.02	94.2
B	23.5	86	90	26.6	94	72	2.00	107.5
C	51.0	153	145	47.8	146	103	1.98	95.5

TABLE 3 Determination of residual-excess (R_{XS}) seeds for patients A, B, and C from Table 2.

Determination of R_{XS}							
Derivation using columns from Table 2	N_{XS} (III–VI)	Number of excess seeds due to i				A_{XS} $\sum_i n_i$	R_{XS} $N_{XS} - \sum_i n_i$
		n_{vol} (II–V)	n_{order} (III–II)	$n_{D90\%}$ (VI) $\left(\frac{100\%}{VIII} - 1\right)$	n_U (VI) $\left(1 - \frac{2U}{VII}\right)$		
A	39	13	–3	3.5	0.55	14.05	24.9
B	18	–8	4	–5.0	0.00	–9	27.0
C	42	7	–8	4.9	–1.04	2.9	39.1

**FIG. 1.** Histogram indicating the frequency of the percent of ordered seeds which were unused per prostate seed implant procedure.**TABLE 4** Average number of excess seeds (N_{XS}), number of excess seeds due to reason (i), and number of residual-excess (R_{XS}) seeds.

	N_{XS}	n_{vol}	n_{order}	$n_{D90\%}$	n_U	R_{XS}
$\bar{n}_i \pm 1\sigma_i$	29.2 ± 13.2	-0.6 ± 13.9	-1.1 ± 3.5	-3.4 ± 6.9	-0.1 ± 1.7	34.4 ± 9.3

Anderson nomogram had been used at our institution, approximately 50% of normalized clinical cases would not have had sufficient seeds.

Figure 3 is a plot of the upper 99.9% confidence interval (CI) of the normalized clinical data, the upper 99.9% CI plus a 5% “cushion,” the normalized clinical data, and the in-house nomogram. If the upper 99.9% CI of the normalized clinical was used for ^{103}Pd seed ordering, 12 out of 226 (5.3%) of normalized clinical cases would not have had sufficient seeds for the implant. The upper 99.9% CI plus a 5% overordering “cushion” would provide enough seeds for all but one patient.

4 | DISCUSSION

Based upon the analysis of 226 patients spanning 6 yr, $25.7 \pm 9.9\%$ of ordered seeds were not implanted. As with most clinical procedures, there will be some discrepancy between what is planned and what occurs at the time of the procedure. We identified four variables in the prostate seed implant flow process which could be used

to account for excess seeds, (a) variances between pre- and intraoperative prostate volume, (b) differences between what was ordered and what should have been ordered based upon the nomogram, (c) $D90\%$ not being equal to 100%, and (d) mean air-kerma strength not being equal to 2 U. We found that none of these variables contributed substantially to the seed excess for our patient sample. The average number of excess seeds was 29.2 ± 13.2 and the average number of residual-excess seeds was 34.4 ± 9.3 . Overordering to assure a sufficient quantity of seeds during the prostate seed implant procedure may be contributing to R_{XS} . If the upper 99.9% CI nomogram was used, 12 patients would not have had enough seeds for their procedure. If the upper 99.9% CI + 5% was used, one patient would not have had enough seeds for their procedure and we could potentially reduce the number of ordered seeds by 13%.

When the clinical data is compared to the other nomograms, two nomograms overestimate the number of required seeds (in-house nomogram and Stock³), two nomograms lay within the range of the clinical data (AAPM TG-64² and Anderson⁶), and one underestimates the number of seeds required (Wang⁷). The disparity between nomograms could be attributed to their variety in formulation. The




FIG. 2. A comparison between four published nomograms, an in-house nomogram, and the normalized clinical data ($n = 226$) for a prescription dose of 125 Gy.




FIG. 3. A comparison of the upper 99.9% confidence interval of the linear regression of the normalized clinical data compared to the in-house nomogram.

nomogram by Wang⁷ is a theoretical derivation where the prostate is modeled as a sphere and radioactivity is considered to be in continuous form. The Anderson nomogram was generated from matched peripheral dose of 13 ¹⁰³Pd implants and 64 ¹²⁵I implants evaluated as if ¹⁰³Pd had been used.⁶

Our institution uses a modified peripheral loading technique, 3D transrectal ultrasound, and dynamic intraoperative delivery.² This 3D method allows the prostate, PTV, organs at risk, needles, seeds, and dose distribution to be visualized in real time. It is possible the in-house nomogram, which has been in use for nearly a decade, is not optimized for the current method of delivery. In the current work, we collected data spanning 6 yr from over 200 ¹⁰³Pd patients to refine our seed ordering nomogram as per the American Brachytherapy Society¹ and AAPM TG-137⁶ recommendations for plan

evaluation using D90% as a volumetric dose metric. Given the disparity between published nomograms, institution-specific nomograms may provide a more efficient means to order and deliver TIPPB.

Reducing the number of excess seeds after a prostate seed implant is beneficial in improving safety but it also yields financial benefits. The savings in US Dollars vs prostate volume is demonstrated in Fig. 4. The savings was calculated by determining the difference in the number of seeds between the in-house nomogram and the upper 99.9% CI + 5% “cushion.” This difference was multiplied by the 2016 Medicare payment rate of \$66.23 per source (HCPCS Code C2641: Brachytherapy source, non-stranded, Palladium-103, per source). By applying the customized nomogram to our sample, we could potentially reduce costs by approximately \$43,000 per year.




FIG. 4. Financial savings per patient introduced by using a clinically derived nomogram for ¹⁰³Pd brachytherapy prostate seed implant.

5 | CONCLUSION

By collecting clinical data spanning 6 yr (2010–2015) and 226 patients, we found that over 85% of clinical cases wasted over 15% of ordered seeds. Substantial disparity between published nomograms was observed. The upper 99.9% CI of our clinical data plus a 5% “cushion” may provide a more reasonable nomogram for ¹⁰³Pd seed ordering for our institution. Other institutions may benefit from a site-specific nomogram. Reducing excess seeds will reduce exposure to staff, reduce the risk of accidental contamination, and reduce cost which may increase the value of prostate brachytherapy compared with other treatment modalities.

ACKNOWLEDGMENTS

All persons who have made substantial contributions to the work reported in the manuscript (e.g., technical help, writing and editing assistance, general support), but who do not meet the criteria for authorship, are named in the Acknowledgments and have given us their written permission to be named. If we have not included an Acknowledgments in our manuscript, then that indicates that we have not received substantial contributions from non-authors. There are no acknowledgments to be made.

AUTHORSHIP

All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication.

CONFLICTS OF INTEREST

The authors whose names are listed immediately below certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.

REFERENCES

- Nag S, Beyer D, Friedland J, Grimm P, Nath R. American brachytherapy society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. *Int J Radiat Oncol Biol Phys.* 1999;44:789–799.
- Yu Y, Anderson LL, Li Z, et al. Permanent prostate seed implant brachytherapy: report of the American Association of Physicists in Medicine Task Group No. 64. *Med Phys.* 1999;26:2054–2076.
- Stock RG, Stone NN, Wesson MF, DeWyngaert JK. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. *Int J Radiat Oncol Biol Phys.* 1995;32:219–225.
- Rosenthal SA, Bittner NH, Beyer DC, et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. *Int J Radiat Oncol Biol Phys.* 2011;79:335–341.
- Parker M, Brown MM, Brown GC, Sharma S. *Evidence-Based to Value-Based Medicine.* Chicago: American Medical Association; 2005. ISBN 1-57947-625-2. Evidence-Based Medicine. 2006 Feb 1;11(1):28-.
- Anderson LL, Moni JV, Harrison LB. A nomograph for permanent implants of palladium-103 seeds. *Int J Radiat Oncol Biol Phys.* 1993;27:129–135.
- Wang X, Potters L. A theoretical derivation of the nomograms for permanent prostate brachytherapy. *Med Phys.* 2001;28:683–687.
- Nath R, Bice W, Butler W, et al. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137. *Med Phys.* 2009;36:5310–5322.